RGS2 as a critical target for asthma therapy


In asthma and chronic obstructive pulmonary disease, activation of G(q)-protein-coupled receptors causes bronchoconstriction. Rgs2-deficient mice, first created by the Siderovski and Penninger labs, revealed enhanced bronchoconstriction to spasmogens and an absence of bronchoprotection by long-acting β(2)-adrenoceptor agonists (LABAs). RGS2 gene expression was identified as a genomic mechanism of bronchoprotection that is induced by glucocorticoids plus LABAs in human airway smooth muscle and provides a rational explanation for the clinical efficacy of inhaled corticosteroid (glucocorticoid)/LABA combinations in obstructive airways diseases. See PNAS 108:19713-8 (2011).

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s